Innate immune sensing of cancer: Clues from an identified role for type I IFNs

Cancer Immunology, Immunotherapy

Volumn 61, Issue 8, 2012, Pages 1343-1347

  Gajewski, Thomas F ^a   Fuertes, Mercedes B ^a   Woo, Seng Ryong ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Dendritic cells; PIVAC 11; T cells; Tumor immunity; Type I IFNs

Indexed keywords

INTERFERON;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DENDRITIC CELL; GENE EXPRESSION PROFILING; HOST RESISTANCE; HUMAN; INNATE IMMUNITY; LYMPHOCYTIC INFILTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR IMMUNITY;

ANIMALS; CONGRESSES AS TOPIC; DENDRITIC CELLS; HUMANS; IMMUNITY, INNATE; INTERFERON TYPE I; MICE; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84865793305     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1305-6     Document Type: Review

References (40)

1. Galon J, Costes A, Sanchez-Cabo F et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960-1964 (Pubitemid 44498003)
2. Mlecnik B, Tosolini M, Kirilovsky A et al (2011) Histopathologic- based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 29:610-618
3. Mahmoud SM, Paish EC, Powe DG et al (2011) Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29:1949-1955
4. Zhang L, Conejo-Garcia JR, Katsaros D et al (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348:203-213 (Pubitemid 36077915)
5. Elder DE, Van Belle P, Elenitsas R et al (1996) Neoplastic progression and prognosis in melanoma. Semin Cutan Med Surg 15:336-348 (Pubitemid 27197972)
6. Gajewski TF, Zha Y, Thurner B, Schuler G (2009) Association of gene expression profile in melanoma and survival to a dendritic cell-based vaccine. J Clin Oncol 27:9002
7. Harlin H, Meng Y, Peterson AC et al (2009) Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 69:3077-3085
8. Gajewski TF, Louahed J, Brichard VG (2010) Gene signature in melanoma associated with clinical activity: A potential clue to unlock cancer immunotherapy. Cancer J 16:399-403
9. Sullivan RJ, Hoshida Y, Brunet J et al (2009) A single center experience with high-dose IL-2 treatment for patients with advanced melanoma and pilot investigation of a novel gene expression signature as a predictor of response. J Clin Oncol 27:15S (Abstract 9003
10. Hamid O, Schmidt H, Nissan A et al (2011) A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 9:204
11. Ji RR, Chasalow SD, Wang L et al (2011) An immune-Active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother
12. Harlin H, Kuna TV, Peterson AC et al (2006) Tumor progression despite massive influx of activated CD8(?) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother 55:1185-1197 (Pubitemid 43992045)
13. Appay V, Jandus C, Voelter V et al (2006) New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol 177:1670-1678 (Pubitemid 44092503)
14. Mortarini R, Piris A, Maurichi A et al (2003) Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-Antigens in human metastatic melanoma. Cancer Res 63:2535-2545 (Pubitemid 36605194)
15. Valmori D, Dutoit V, Rubio-Godoy V et al (2001) Frequent cytolytic T-cell responses to peptide MAGE-A10(254-262) in melanoma. Cancer Res 61:509-512 (Pubitemid 32128608)
16. Peterson AC, Harlin H, Gajewski TF (2003) Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advancedmelanoma. JClinOncol 21:2342-2348 (Pubitemid 46628465)
17. Jager E, Chen YT, Drijfhout JW et al (1998) Simultaneous humoral and cellular immune response against cancer-Testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187:265-270 (Pubitemid 28060443)
18. Darnell RB, Posner JB (2006) Paraneoplastic syndromes affecting the nervous system. Semin Oncol 33:270-298 (Pubitemid 43849931)
19. Wang X, Yu J, Sreekumar A et al (2005) Autoantibody signatures in prostate cancer. N Engl J Med 353:1224-1235 (Pubitemid 41345944)
20. Gajewski TF (2007) Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 13:5256-5261 (Pubitemid 47510348)
21. Blank C, Brown I, Peterson AC et al (2004) PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 64:1140-1145 (Pubitemid 38176921)
22. Brown IE, Blank C, Kline J et al (2006) Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection. J Immunol 177:4521-4529 (Pubitemid 44469783)
23. Kline J, Brown IE, Zha YY et al (2008) Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res 14:3156-3167
24. Uyttenhove C, Pilotte L, Theate I et al (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9:1269-1274 (Pubitemid 37279849)
25. Fuertes MB, Kacha AK, Kline J et al (2011) Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}? dendritic cells. J Exp Med
26. Sancho D, Joffre OP, Keller AM et al (2009) Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature 458:899-903
27. Diamond MS, Kinder M, Matsushita H et al (2011) Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 208:1989-2003
28. Hildner K, Edelson BT, Purtha WE et al (2008) Batf3 deficiency reveals a critical role for CD8alpha? dendritic cells in cytotoxic T cell immunity. Science 322:1097-1100
29. Barton GM, Medzhitov R (2002) Toll-like receptors and their ligands. Curr Top Microbiol Immunol 270:81-92 (Pubitemid 35448154)
30. Martinon F, Mayor A, Tschopp J (2009) The inflammasomes: guardians of the body. Annu Rev Immunol 27:229-265
31. Sancho D, Mourao-Sa D, Joffre OP et al (2008) Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-Type lectin. J Clin Invest 118:2098-2110 (Pubitemid 351872329)
32. Ishikawa H, Barber GN (2008) STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455:674-678
33. McCartney S, Vermi W, Gilfillan S et al (2009) Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)- mediated activation of mouse NK cells. J Exp Med 206: 2967-2976
34. Barber GN (2011) Innate immune DNA sensing pathways: STING, AIMII and the regulation of interferon production and inflammatory responses. Curr Opin Immunol 23:10-20
35. Lister MF, Sharkey J, Sawatzky DA et al (2007) The role of the purinergic P2X7 receptor in inflammation. J Inflamm (Lond) 4:5
36. Muller T, Vieira RP, Grimm M et al (2011) A potential role for P2X7R in allergic airway inflammation in mice and humans. Am J Respir Cell Mol Biol 44:456-464
37. Apetoh L, Ghiringhelli F, Tesniere A et al (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13:1050-1059 (Pubitemid 47517504)
38. Ghiringhelli F, Apetoh L, Tesniere A et al (2009) Activation of the NLRP3 inflammasome in dendritic cells induces IL-1betadependent adaptive immunity against tumors. Nat Med 15:1170- 1178
39. Niewold TB, Hua J, Lehman TJ et al (2007) High serum IFNalpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 8:492-502 (Pubitemid 47365615)
40. Salloum R, Franek BS, Kariuki SN et al (2010) Genetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon-Alpha activity in lupus patients. Arthr Rheum 62:553-561